Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

Share this content:
Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression
Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

Pembrolizumab provides benefit over ipilimumab in patients with advanced melanoma, regardless of tumor PD-L1 expression status or number of prior therapies, a study presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting has shown.1

The KEYNOTE-006 trial demonstrated that pembrolizumab provides superior overall and progression-free survival with a lower rate of grade 3 to 5 adverse events compared with ipilimumab in patients with advanced melanoma who have received no more than 1 prior therapy. Investigators sought to conduct an analysis of KEYNOTE-006 evaluating the impact of PD-L1 expression and prior therapy on outcomes.

Continue Reading Below

The KEYNOTE-006 study enrolled 834 patients, of which 80% were PD-L1-positive and 18% were PD-L1-negative. Approximately two-thirds were treatment-naïve and the other one-third had previously received 1 line of therapy.

Participants were randomly assigned to receive pembrolizumab 10 mg/kg IV every 2 or 3 weeks, or ipilimumab 3 mg/kg IV every 3 weeks. Pembrolizumab was given for 24 months or until disease progression or unacceptable toxicity, while ipilimumab was given for 4 cycles or until progression or intolerable toxicity.

Results showed that overall survival was improved with pembrolizumab in all subgroups expect those who were PD-L1-negative; however, the sample size in that group was small.

Researchers found that patients who were treatment-naïve and had PD-L1-positive tumors benefitted the most from pembrolizumab therapy.

The study further demonstrated that increasing PD-L1 expression was associated with improved outcomes with pembrolizumab vs ipilimumab when PD-L1 was scored as immunohistochemistry (IHC) 0 (0% staining), 1 ( < 1%), 2 (1%-9%), 3 (10%-32%), 4 (33%-65%), and 5 ( ≥ 66%).


1. Daud A, Blank CU, Robert C, et al. KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. J Clin Oncol. 2016; 34(suppl):Abstr 9513.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs